Lisanti Capital Growth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Lisanti Capital Growth’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-43,040	Closed	-$2M	–	119
2025 Q4	$2M	Buy	43,040 +20,150	+88%	+$897K	0.47%	83
2025 Q3	$953K	Buy	+22,890	New	+$732K	0.23%	93
2025 Q1	–	Sell	-82,700	Closed	-$4.23M	–	120
2024 Q4	$4.23M	Sell	82,700 -25,875	-24%	-$1.45M	1.02%	40
2024 Q3	$5.55M	Buy	108,575 +25,195	+30%	+$1.3M	1.41%	18
2024 Q2	$3.73M	Buy	83,380 +14,155	+20%	+$654K	0.9%	56
2024 Q1	$3.24M	Sell	69,225 -31,020	-31%	-$1.21M	0.79%	61
2023 Q4	$3.57M	Buy	100,245 +50,265	+101%	+$1.54M	0.84%	56
2023 Q3	$1.49M	Buy	+49,980	New	+$1.03M	0.23%	109

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Lisanti Capital Growth's CRNX Position: Q1 2026 in Review

Lisanti Capital Growth sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 43,040 shares — an estimated $2M sold.

Lisanti Capital Growth first reported a position in CRNX in Q3 2023 and held it in 8 quarters. The position peaked at $5.55M in Q3 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

Lisanti Capital Growth reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Lisanti Capital Growth sold 43,040 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $2M.
Lisanti Capital Growth first reported a position in Crinetics Pharmaceuticals in Q3 2023 and held it in 8 quarters.
Lisanti Capital Growth's Crinetics Pharmaceuticals position peaked at $5.55M in Q3 2024.
243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.